Contribution of Mitochondrial Activity to Doxorubicin-Resistance in Osteosarcoma Cells

Contribution of Mitochondrial Activity to Doxorubicin-Resistance in Osteosarcoma Cells

Osteosarcoma is considered the most common bone tumor affecting children and young adults. The standard of care is chemotherapy; however, the onset of drug resistance still jeopardizes osteosarcoma patients, thus making it necessary to conduct a thorough investigation of the possible mechanisms behi...

Full description

Bibliographic Details
Main Authors:	Isabella Giacomini, Margherita Cortini, Mattia Tinazzi, Nicola Baldini, Veronica Cocetta, Eugenio Ragazzi, Sofia Avnet, Monica Montopoli
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Cancers
Subjects:	osteosarcoma cancer chemotherapy doxorubicin drug resistance metabolism
Online Access:	https://www.mdpi.com/2072-6694/15/5/1370

Similar Items

A Novel Approach on Drug Delivery: Investigation of A New Nano-Formulation of Liposomal Doxorubicin and Biological Evaluation of Entrapped Doxorubicin on Various Osteosarcoma Cell Lines
by: Fateme Haghiralsadat, et al.
Published: (2017-05-01)

The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis
by: Bin Zhang, et al.
Published: (2020-02-01)

Endogenous Extracellular Matrix Regulates the Response of Osteosarcoma 3D Spheroids to Doxorubicin
by: Margherita Cortini, et al.
Published: (2023-02-01)

Doxorubicin Dose Deintensification in Pediatric Osteosarcoma, Is Less Better?
by: Hadeel Halalsheh, et al.
Published: (2023-07-01)

Chitosan-Boric Acid Scaffolds for Doxorubicin Delivery in the Osteosarcoma Treatment
by: Luka Dornjak, et al.
Published: (2022-11-01)

Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines
by: Ya-Ting Yang, et al.
Published: (2022-08-01)

EGCG regulated osteolytic microenvironment to enhance the antitumor effect of DOX on orthotopic osteosarcoma
by: Dongcai Hu, et al.
Published: (2022-07-01)

Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma
by: Martina Godel, et al.
Published: (2020-06-01)

Osteosarcoma cells can reproduce into tumorigenic cells by escaping chemotherapy-induced cell senescence
by: ZHANG Liang, LIU Ming-yong, LIU Peng, XUE Xin, ZHANG Liang-min, GUO Qiao-nan, ZHAO Jian-hua
Published: (2020-02-01)

Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group
by: Lisa M. Kopp, et al.
Published: (2019-10-01)

In Vitro Delivery and Controlled Release of Doxorubicin for Targeting Osteosarcoma Bone Cancer
by: Tengku Azmi Tengku Ibrahim, et al.
Published: (2013-08-01)

MALAT-1 is Associated with the Doxorubicin Resistance in U-2OS Osteosarcoma Cells
by: Liu C, et al.
Published: (2021-09-01)

A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro
by: Wei H, et al.
Published: (2019-11-01)

Doxorubicin-Loaded Lipid Nanoparticles Coated with Calcium Phosphate as a Potential Tool in Human and Canine Osteosarcoma Therapy
by: Daniela Chirio, et al.
Published: (2022-06-01)

Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma
by: Renna Qiu, et al.
Published: (2020-01-01)

Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
by: Ingrid Lilienthal, et al.
Published: (2020-09-01)

Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with IfosfamideDoxorubicin for Osteosarcoma
by: Mozhgan Aalam Samimi, et al.
Published: (2014-03-01)

Development, Characterization and Cell Viability Inhibition of PVA Spheres Loaded with Doxorubicin and 4′-Amino-1-Naphthyl-Chalcone (D14) for Osteosarcoma
by: Viviane Seba, et al.
Published: (2021-08-01)

Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis
by: Wei H, et al.
Published: (2022-08-01)

Long non-coding RNA LINC00426 contributes to doxorubicin resistance by sponging miR-4319 in osteosarcoma
by: Lulin Wang, et al.
Published: (2020-07-01)

Chlorogenic Acid Enhances Doxorubicin-Mediated Cytotoxic Effect in Osteosarcoma Cells
by: Alessia Salzillo, et al.
Published: (2021-08-01)

Curcumin-Loaded Nanoparticles Impair the Pro-Tumor Activity of Acid-Stressed MSC in an In Vitro Model of Osteosarcoma
by: Gemma Di Pompo, et al.
Published: (2021-05-01)

Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy
by: Yongshuang Li, et al.
Published: (2020-01-01)

The Sensitization of Melatonin in Osteosarcoma Cells by Suppression of Anti-Apoptotic Proteins
by: Seyed Mostafa Mir, et al.
Published: (2020-06-01)

Synthesis, characterization, and evaluation of pH-sensitive doxorubicin-loaded functionalized graphene oxide in osteosarcoma cells
by: Forough Alemi, et al.
Published: (2023-05-01)

A new approach to the development and assessment of doxorubicin-loaded nanoliposomes for the treatment of osteosarcoma in 2D and 3D cell culture systems
by: Mastaneh Parchami, et al.
Published: (2023-05-01)

Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance
by: Dong-Yu Wang, et al.
Published: (2016-05-01)

m6A-modified circARHGAP12 promotes the aerobic glycolysis of doxorubicin-resistance osteosarcoma by targeting c-Myc
by: Dawei Zhang, et al.
Published: (2024-01-01)

SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition
by: Wanchun Wang, et al.
Published: (2018-02-01)

Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate at a public hospital in Brazil
by: Marilia Polo Minguete-e-Silva, et al.
Published: (2021-10-01)

Black phosphorus quantum dots camouflaged with platelet-osteosarcoma hybrid membrane and doxorubicin for combined therapy of osteosarcoma
by: Yanlong Xu, et al.
Published: (2023-07-01)

Mechanisms of Resistance to Conventional Therapies for Osteosarcoma
by: Louise Marchandet, et al.
Published: (2021-02-01)

Sustained and Targeted Delivery of Self-Assembled Doxorubicin Nonapeptides Using pH-Responsive Hydrogels for Osteosarcoma Chemotherapy
by: Jie Zhu, et al.
Published: (2023-02-01)

Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma in vitro and in vivo
by: Jinkui Wang, et al.
Published: (2022-12-01)

Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
by: K Alimoghadam, et al.
Published: (2004-03-01)

Piperine improves the sensitivity of osteosarcoma cells to doxorubicin by inducing apoptosis and inhibiting the PI3K/AKT/GSK-3β pathway
by: Yubin Qi, et al.
Published: (2023-03-01)

Chemotherapy in the management of periosteal osteosarcoma: A narrative review
by: Tarek Assi, et al.
Published: (2021-10-01)

SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin
by: Evelien G. E. Hurkmans, et al.
Published: (2022-11-01)

Neopetroside-B alleviates doxorubicin-induced cardiotoxicity via mitochondrial protection
by: Chang Shin Yoon, et al.
Published: (2023-09-01)

Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma
by: Yong Bicheng, et al.
Published: (2012-09-01)